SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lineage, Inc. (NASDAQ: LINE)

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lineage, Inc. (NASDAQ: LINE) GlobeNewswire September 22, 2025 NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or […]

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against KinderCare Learning Companies, Inc. (NYSE: KLC)

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against KinderCare Learning Companies, Inc. (NYSE: KLC) GlobeNewswire September 22, 2025 NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO) GlobeNewswire September 22, 2025 NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Declares Quarterly Preferred Stock Dividends GlobeNewswire September 22, 2025 EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 GlobeNewswire September 22, 2025 PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clinical

DeFi Development Corp. and Frametric Labs To Launch Korea’s First Solana DAT, DFDV Korea

DeFi Development Corp. and Frametric Labs To Launch Korea's First Solana DAT, DFDV Korea GlobeNewswire September 22, 2025 BOCA RATON, FL, Sept. 22, 2025 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced an LOI for the

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Snap Inc. (NYSE: SNAP)

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Snap Inc. (NYSE: SNAP) GlobeNewswire September 22, 2025 NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lockheed Martin Corporation (NYSE: LMT)

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lockheed Martin Corporation (NYSE: LMT) GlobeNewswire September 22, 2025 NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting up to three years of patient follow-up and

Canadians are snacking more, drinking less and looking for more value for their shrinking dollar: 2025 Foodservice Facts report

Canadians are snacking more, drinking less and looking for more value for their shrinking dollar: 2025 Foodservice Facts report GlobeNewswire September 22, 2025 Toronto, Sept. 22, 2025 (GLOBE NEWSWIRE) — Three in four Canadians (75%) are eating out less often due to the rising cost of living, according to Restaurants Canada's 2025 Foodservice Facts report

Scroll to Top